Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Open accessThe DOI matches its Crossref record; 506 of the 506 references it cites were found in a registry or an index.
Abstract
Drug designing and development is an important area of research for pharmaceutical companies and chemical scientists. However, low efficacy, off-target delivery, time consumption, and high cost impose a hurdle and challenges that impact drug design and discovery. Further, complex and big data from genomics, proteomics, microarray data, and clinical trials also impose an obstacle in the drug discovery pipeline. Artificial intelligence and machine learning technology play a crucial role in drug discovery and development. In other words, artificial neural networks and deep learning algorithms have modernized the area. Machine learning and deep learning algorithms have been implemented in several drug discovery processes such as peptide synthesis, structure-based virtual screening, ligand-based virtual screening, toxicity prediction, drug monitoring and release, pharmacophore modeling, quantitative structure-activity relationship, drug repositioning, polypharmacology, and physiochemical activity. Evidence from the past strengthens the implementation of artificial intelligence and deep learning in this field. Moreover, novel data mining, curation, and management techniques provided critical support to recently developed modeling algorithms. In summary, artificial intelligence and deep learning advancements provide an excellent opportunity for rational drug design and discovery process, which will eventually impact mankind. The primary concern associated with drug design and development is time consumption and production cost. Further, inefficiency, inaccurate target delivery, and inappropriate dosage are other hurdles that inhibit the process of drug delivery and development. With advancements in technology, computer-aided drug design integrating artificial intelligence algorithms can eliminate the challenges and hurdles of traditional drug design and development. Artificial intelligence is referred to as superset comprising machine learning, whereas machine learning comprises supervised learning, unsupervised learning, and reinforcement learning. Further, deep learning, a subset of machine learning, has been extensively implemented in drug design and development. The artificial neural network, deep neural network, support vector machines, classification and regression, generative adversarial networks, symbolic learning, and meta-learning are examples of the algorithms applied to the drug design and discovery process. Artificial intelligence has been applied to different areas of drug design and development process, such as from peptide synthesis to molecule design, virtual screening to molecular docking, quantitative structure-activity relationship to drug repositioning, protein misfolding to protein-protein interactions, and molecular pathway identification to polypharmacology. Artificial intelligence principles have been applied to the classification of active and inactive, monitoring drug release, pre-clinical and clinical development, primary and secondary drug screening, biomarker development, pharmaceutical manufacturing, bioactivity identification and physiochemical properties, prediction of toxicity, and identification of mode of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Artificial Intelligence may allow for more accurate personalisation of therapy to predict the optimum ‘cocktail’ of mono agonist therapies based on the genetics and metabolomics of an individual and may quicken the process of drug development [70, 71].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These authors trained a DL algorithm on a large dataset of known cancer-related compounds and their corresponding biological activity. As an output, novel compounds with high potential for future cancer treatment were obtained, demonstrating the ability of this method to discover new therapeutic candidates.”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, the successful use of AI to identify novel compounds for the treatment of cancer has recently been reported by Gupta, R., et al. [21].”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ImageNet classification with deep convolutional neural networks
Krizhevsky, A., Sutskever, I., & Hinton, G. E. (2017) · Communications of the ACM · doi:10.1145/3065386 · Cited by 112,155 · cited 1×
“AlexNet, a convolutional neural network, was created by Alex Krizhevsky around 2012, which helped in strengthening the speed and dropout using rectified linear units [33].”
MethodHochreiter, S., & Schmidhuber, J. (1997) · Neural Computation · doi:10.1162/neco.1997.9.8.1735 · Cited by 102,318 · cited 1×
“After two years, in 1997, Jürgen Schmidhuber and Sepp Hochreiter developed long short-term memory (LSTM) for recurrent neural networks [30].”
BackgroundLeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
ImageNet: A large-scale hierarchical image database
Deng, J., Dong, W., Socher, R., Li, L.-J., Li, K., & Fei-Fei, L. (2009) · 2009 IEEE Conference on Computer Vision and Pattern Recognition · doi:10.1109/cvpr.2009.5206848 · Cited by 65,333 · cited 1×
“In 2009, Fei-Fei Li launched ImageNet, which is a free database containing millions of labeled images that can be used for research purposes [32].”
BackgroundCortes, C., & Vapnik, V. (1995) · Machine Learning · doi:10.1007/bf00994018 · Cited by 59,421
Cortes, C., & Vapnik, V. (1995) · Machine-mediated learning · doi:10.1023/a:1022627411411 · Cited by 48,445 · cited 1×
“In 1995, Corinna Cortes and Vladimir Vapnik developed support vector machines (SVM) to map and recognize similar data [29].”
BackgroundLearning representations by back-propagating errors
Rumelhart, D. E., Hinton, G. E., & Williams, R. J. (1986) · Nature · doi:10.1038/323533a0 · Cited by 31,892 · cited 1×
“David Rumelhart, Geoffrey Hinton, and Ronald J. Williams published a paper entitled “Learning Representations by Back-propagating Errors” in 1986, which demonstrated that backpropagation could provide an improvement in shape recognition and word prediction [26].”
BackgroundAdvances in neural information processing systems 7
Cios, K., & Shields, M. (1997) · Neurocomputing · doi:10.1016/s0925-2312(97)90018-7 · Cited by 22,059
Deep learning in neural networks: an overview
Schmidhuber, J. (2015) · Neural Networks · doi:10.1016/j.neunet.2014.09.003 · Cited by 18,570 · cited 1×
“…uses supervised learning, where the model is trained to use labeled data, which means that the input has been tagged with corresponding preferred output labels or uses unsupervised learning, where the model is trained to use unlabeled data but looks for recurring patterns from the input data [15].”
A logical calculus of the ideas immanent in nervous activity
McCulloch, W. S., & Pitts, W. (1943) · The Bulletin of Mathematical Biophysics · doi:10.1007/bf02478259 · Cited by 18,566
Generative adversarial networks
Goodfellow, I., Pouget-Abadie, J., Mirza, M., Xu, B., Warde-Farley, D., Ozair, S., Courville, A., & Bengio, Y. (2020) · Communications of the ACM · doi:10.1145/3422622 · Cited by 18,384
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367 · cited 1×
“Recently, a freely accessible, user-friendly graphical interface SwissADME (http:// www. swiss adme. ch) was developed to evaluate the compatibility of the drug and its pharmacokinetic actions [145].”
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749 · cited 1×
“Further, STRING (https:// string-db. org/) is another text mining-driven data-base containing a myriad of information on protein–protein interactions for various organisms [91].”
BackgroundGene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288 · cited 1×
“NCBI Gene Expression Omnibus (GEO) (https:// www. ncbi. nlm. nih. gov/ geo/) [41], The Cancer Genome Atlas (TCGA) (https:// www. cancer. gov/ about-nci/ organ izati on/ ccg/ resea rch/ struc tural-genom ics/ tcga) [42], Arrayexpress (https:// www. ebi . ac . uk / array expre ss/) [43], are some of…”
BackgroundBackpropagation Applied to Handwritten Zip Code Recognition
LeCun, Y., Boser, B., Denker, J. S., Henderson, D., Howard, R. E., Hubbard, W., & Jackel, L. D. (1989) · Neural Computation · doi:10.1162/neco.1989.1.4.541 · Cited by 11,891 · cited 1×
“Soon, in 1989, Yann LeCun gave the first practical demonstration of backpropagation at Bell Labs [27].”
BackgroundWatkins, C. J. C. H., & Dayan, P. (1992) · Machine Learning · doi:10.1007/bf00992698 · Cited by 9,083
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
DeepFace: Closing the Gap to Human-Level Performance in Face Verification
Taigman, Y., Yang, M., Ranzato, M., & Wolf, L. (2014) · 2014 IEEE Conference on Computer Vision and Pattern Recognition · doi:10.1109/cvpr.2014.220 · Cited by 6,542 · cited 1×
“Similarly, “Deep Face” was developed and released in 2014 to identify faces with 97.5% accuracy [36].”
BackgroundInfluentialComputing Machinery and Intelligence (1950)
Turing, A. (2004) · The Essential Turing · doi:10.1093/oso/9780198250791.003.0017 · Cited by 6,118
Fukushima, K. (1980) · Biological Cybernetics · doi:10.1007/bf00344251 · Cited by 5,759 · cited 4×
“From the past two decades, the development of efficient and advanced systems for the targeted delivery of therapeutic agents with maximum efficiency and minimum risks has imposed a great challenge among chemical and biological scientists [1].”
BackgroundInfluentialPires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00104 · Cited by 5,716
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718 · cited 1×
“Recently, drug repurposing has emerged as an innovative approach to minimize drug development duration that usually involves data mining and AI [438].”
BackgroundSome Studies in Machine Learning Using the Game of Checkers
Samuel, A. L. (1959) · IBM Journal of Research and Development · doi:10.1147/rd.33.0210 · Cited by 4,443 · cited 1×
“In 1952, Arthur L. Samuel popularized the term “machine learning” by writing a checker-playing program for IBM [20].”
BackgroundBeyond the hype: Big data concepts, methods, and analytics
Gandomi, A., & Haider, M. (2015) · International Journal of Information Management · doi:10.1016/j.ijinfomgt.2014.10.007 · Cited by 4,226 · cited 1×
“The three main characteristic features of big data are volume, velocity, and variety, where volume represents the huge amount and mass of data generated, velocity represents the rate at which these data are being reproduced, and variety represents heterogenicity present in the data sets [38].”
BackgroundBuniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1120 · Cited by 4,000 · cited 1×
“GWAS central (https:// www. gwasc entral. org/) [46], NHGRI-EBI GWAS Catalog (https:// www. ebi. ac. uk/ gwas/ home) [47] are some of the repositories which contain GWAS data.”
BackgroundPubChem in 2021: new data content and improved web interfaces
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa971 · Cited by 3,953 · cited 1×
“Likewise, PubChem (https:// pubch em. ncbi. nlm. nih. gov/) [54] is a freely accessible chemical database that contains data of various chemical structures, including their biological, physical, chemical, and toxic properties [55].”
BackgroundWatkins, C. J. C. H., & Dayan, P. (1992) · Machine Learning · doi:10.1023/a:1022676722315 · Cited by 3,907
Improved protein structure prediction using potentials from deep learning
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1923-7 · Cited by 3,378 · cited 1×
“…of proteins in two steps: (i) firstly, using a CNN it transforms an amino acid sequence of a protein to distance matrix as well as a torsion angle matrix, (ii) secondly, using a gradient optimization technique it translates these two matrices into the three-dimensional structure of a protein [75].”
MethodInnovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 1×
“It usually takes 12 years to bring a new drug to the market, which can cost up to 3 billion USD [445].”
BackgroundPubChem 2019 update: improved access to chemical data
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1033 · Cited by 3,249 · cited 1×
“Likewise, PubChem (https:// pubch em. ncbi. nlm. nih. gov/) [54] is a freely accessible chemical database that contains data of various chemical structures, including their biological, physical, chemical, and toxic properties [55].”
BackgroundApplications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228 · cited 1×
“In addition to that, very less drug discovery data are available to train AI models [448].”
BackgroundZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
ProTox-II: a webserver for the prediction of toxicity of chemicals
Banerjee, P., Eckert, A. O., Schrey, A. K., & Preissner, R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky318 · Cited by 3,195
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
Leinonen, R., Sugawara, H., Shumway, M., & on behalf of the International Nucleotide Sequence Database Collaboration (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1019 · Cited by 2,746 · cited 1×
“For sequencing data, we have public repositories like Sequence read archive (https:// www. ncbi. nlm. nih. gov/ sra) [49], which contains sequencing data obtained from next-gen sequencing technology.”
MethodPiñero, J., Bravo, À., Queralt-Rosinach, N., Gutiérrez-Sacristán, A., Deu-Pons, J., Centeno, E., García-García, J., Sanz, F., & Furlong, L. I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw943 · Cited by 2,680 · cited 1×
“Likewise, DisGeNET (https:// www. disge net. org/) is a text mining-driven database that contains a plethora of information on gene-disease and variants-disease relationships [90].”
BackgroundA Deep Learning Approach to Antibiotic Discovery
Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.021 · Cited by 2,463 · cited 1×
“Moreover, in comparison with AI and ML algorithms, DL provides a much more flexible architecture to create a neural network for a specific problem [477–480].”
ResultChEMBL: towards direct deposition of bioassay data
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P., Nowotka, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1075 · Cited by 2,372 · cited 1×
“Further, the ChEMBL database (https:// www. ebi. ac. uk/ chembl/) [56] is an open access big database containing data of numerous bioactive compounds exhibiting drug-like properties [57].”
BackgroundMolecular Docking: Shifting Paradigms in Drug Discovery
Pinzi, L., & Rastelli, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184331 · Cited by 2,344 · cited 1×
“Now molecular docking is being used in conjugation with MD simulation and AI-based tools in different areas of drug discovery like VS, target identification, polypharmacology, and drug repurposing [296].”
MethodArtificial intelligence in medicine
Hamet, P., & Tremblay, J. (2017) · Metabolism · doi:10.1016/j.metabol.2017.01.011 · Cited by 2,334
admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties
Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., Liu, G., Lee, P. W., & Tang, Y. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300367a · Cited by 2,222 · cited 1×
“For this different web-based tools have been developed such as LimTox (http:// limtox. bioin fo. cnio. es/) [321], pkCSM (http:// biosig. unime lb. edu. au/ pkcsm/) [322], admetSAR (http:// lmmd. ecust. edu. cn/ admet sar2/) [323], and Toxtree (http:// toxtr ee. sourc eforge. net/) [324].”
MethodErtl, P., & Schuffenhauer, A. (2009) · Journal of Cheminformatics · doi:10.1186/1758-2946-1-8 · Cited by 1,939 · cited 1×
“In one study, the researchers utilized the indolent space portrayal to prepare a model dependent on the quantitative estimate of drug-likeness (QED) drug-similarity score and the manufactured availability score synthetic accessibility score (SAS ) [425].”
BackgroundPlanning chemical syntheses with deep neural networks and symbolic AI
Segler, M. H. S., Preuss, M., & Waller, M. P. (2018) · Nature · doi:10.1038/nature25978 · Cited by 1,847
SwissTargetPrediction: a web server for target prediction of bioactive small molecules
Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O., & Zoete, V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku293 · Cited by 1,791
The rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770 · cited 1×
“The AI-based tools developed for predicting bio-physical and biochemical properties of compounds include molecular fingerprinting, a SMILES format, Coulomb matrices, and potential energy measurements, which are used in the DNN training phase [299, 300].”
MethodDeepDTA: deep drug–target binding affinity prediction
Öztürk, H., Özgür, A., & Ozkirimli, E. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty593 · Cited by 1,696 · cited 1×
“DL approaches such as DeepDTA (https:// github. com/ hkmzt rk/ DeepD TA) [314], and PADME [315] predict drug-target binding affinity, which depends on the 3-”
MethodSTITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data
Szklarczyk, D., Santos, A., von Mering, C., Jensen, L. J., Bork, P., & Kuhn, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1277 · Cited by 1,687 · cited 1×
“In addition, STITCH (http:// stitch. embl. de/) is another text mining-driven data-base, which contains information on interactions between proteins and chemicals/small molecules [92].”
BackgroundProdrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630 · cited 1×
“…with a small number of people; Phase 2, drug efficacy testing with the small number of human subjects affected by a particular disease; Phase 3, efficacy studies with a large number of patients and after passing the clinical trials FDA reviews it for approval and commercialization [451, 452].”
BackgroundNetwork-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020) · Cell Discovery · doi:10.1038/s41421-020-0153-3 · Cited by 1,597
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585 · cited 1×
“Thus, the use of AI is mainly associated with a need to reduce attrition and costs [444].”
BackgroundDeep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573 · cited 2×
“With the help of GEN-TRL (https:// github. com / insil icome dicine/ GENTRL), Zhavoronkov et al. discovered novel inhibitors of an enzyme, DDR1 kinase [118].”
BackgroundMethodGenerating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks
Segler, M. H. S., Kogej, T., Tyrchan, C., & Waller, M. P. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00512 · Cited by 1,537
Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17
Ruddigkeit, L., van Deursen, R., Blum, L. C., & Reymond, J.-L. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300415d · Cited by 1,505 · cited 1×
“Further, it is a huge task to find a new drug when there are ~ 10 60 existing drug-like molecules [446].”
BackgroundVirtual Computational Chemistry Laboratory – Design and Description
Tetko, I. V., Gasteiger, J., Todeschini, R., Mauri, A., Livingstone, D., Ertl, P., Palyulin, V. A., Radchenko, E. V., Zefirov, N. S., Makarenko, A. S., et al. (2005) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-005-8694-y · Cited by 1,500 · cited 3×
“…r ong p r e d i c ti v e po w e r o f D ee p D r ug [ 420 ] vcclab. org/ lab/ pclie nt/) [304], E-DRAGON (http:// www. vcclab. org/ lab/ edrag on/) [304], ChemSpider (http:// www. chems pider. com/) [306], SPARC (http:// sparc. chem. uga. edu/ sparc/) [307], and OSIRIS property explorer (https://…”
BackgroundInfluentialThe ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492
Deep learning for computational biology
Angermueller, C., Pärnamaa, T., Parts, L., & Stegle, O. (2016) · Molecular Systems Biology · doi:10.15252/msb.20156651 · Cited by 1,473 · cited 1×
“…its algorithm over time with the help of a constant feedback loop and lastly DL where there are many layers of ML algorithms which is called as a brain-inspired family of algorithms which mimics human brain but requires high computational power for training and big data to succeed [16, 17].”
BackgroundComputing Machinery and Intelligence
Turing, A. M. (2009) · Parsing the Turing Test · doi:10.1007/978-1-4020-6710-5_3 · Cited by 1,367
Molecular de-novo design through deep reinforcement learning
Olivecrona, M., Blaschke, T., Engkvist, O., & Chen, H. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-017-0235-x · Cited by 1,324 · cited 1×
“A similar methodology was likewise effectively utilized for the development of novel peptide structures [430].”
MethodRole of Molecular Dynamics and Related Methods in Drug Discovery
De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01684 · Cited by 1,297
Exploiting Generative Models in Discriminative Classifiers
Jaakkola, T., & Haussler, D. H. (1998) · Cited by 1,271
Burley, S. K., Berman, H. M., Bhikadiya, C., Bi, C., Chen, L., Di Costanzo, L., Christie, C., Dalenberg, K., Duarte, J. M., Dutta, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1004 · Cited by 1,243 · cited 1×
“Further, the protein data bank (PDB) (https:// www. rcsb. org/) [62] is another freely accessible online repository that contains data of three-dimensional structures of proteins, DNA, RNA [63].”
BackgroundDeep reinforcement learning for de novo drug design
Popova, M., Isayev, O., & Tropsha, A. (2018) · Science Advances · doi:10.1126/sciadv.aap7885 · Cited by 1,182 · cited 3×
“Likewise, Popova et al. 2018 designed a deep reinforcement learning-based algorithm, referred to as ReLeaSE (https:// github. com/ isayev/ ReLea SE), for de novo drug design.”
MethodInfluentialPolypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131 · cited 1×
“It is best suited for designing a promising therapeutic agent for more complex diseases such as cancer, neurodegenerative disease (NDDs), diabetes, heart failure, and many others [353–355].”
BackgroundNeocognitron: A hierarchical neural network capable of visual pattern recognition
Fukushima, K. (1988) · Neural Networks · doi:10.1016/0893-6080(88)90014-7 · Cited by 1,097 · cited 1×
“He also developed the first convolutional neural network (CNN) which was based on the visual cortex organization found in animals [25] [Fig.”
BackgroundDeepTox: toxicity prediction using deep learning
Mayr, A., Klambauer, G., Unterthiner, T., & Hochreiter, S. (2016) · Frontiers in Environmental Science · doi:10.3389/fenvs.2015.00080 · Cited by 1,081
Drug discovery with explainable artificial intelligence
Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00236-4 · Cited by 1,063 · cited 1×
“However, the introduction of AI has given a broader scope to develop new approaches that can improve and optimize drug discovery [442].”
BackgroundConservation of gene order: a fingerprint of proteins that physically interact
Dandekar, T. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01274-2 · Cited by 1,041 · cited 1×
“If two proteins’ genes are not close by in the genome, then this method cannot reliably predict an interaction between these two genes [156, 157].”
Salmina, E., Haider, N., & Tetko, I. (2015) · Molecules · doi:10.3390/molecules21010001 · Cited by 1,041
Fogel, D. B. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.001 · Cited by 1,035
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022 · cited 2×
“They also intend to establish a uniform data format, which is technically challenging [161].”
BackgroundMethodArtificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018 · cited 1×
“Hence, there is a dire need for new drug targets and drug compounds, which can alleviate the symptoms and mitigate the diseased conditions of the central nervous systems [462].”
BackgroundRethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894 · cited 1×
“The AI-based tools developed for predicting bio-physical and biochemical properties of compounds include molecular fingerprinting, a SMILES format, Coulomb matrices, and potential energy measurements, which are used in the DNN training phase [299, 300].”
MethodDong, J., Wang, N.-N., Yao, Z.-J., Zhang, L., Cheng, Y., Ouyang, D., Lu, A.-P., & Cao, D.-S. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0283-x · Cited by 889
Radhakrishnan, A., Nanjappa, V., Raja, R., Sathe, G., Puttamallesh, V. N., Jain, A. P., Pinto, S. M., Balaji, S. A., Chavan, S., Sahasrabuddhe, N. A., et al. (2017) · Scientific Reports · doi:10.1038/srep46864 · Cited by 825
Building high-level features using large scale unsupervised learning
Ranzato, M., Monga, R., Devin, M., Chen, K., Corrado, G. S., Dean, J., Le, Q. V., & Ng, A. Y. (2012) · International Conference on Machine Learning · Cited by 823
Beck, B. R., Shin, B., Choi, Y., Park, S., & Kang, K. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.025 · Cited by 816 · cited 1×
“Beck et al. 2020 conducted a study to predict commercially available antiviral drugs as a potential therapeutic agent against novel coronavirus (SARS-CoV-2) through DeepDTA [316].”
BackgroundGlobal mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811 · cited 1×
“Repositioning drugs might be successful due to the possibility of multiple-target involvement in multiple diseases [267–269].”
BackgroundDeep learning for computational chemistry
Goh, G. B., Hodas, N. O., & Vishnu, A. (2017) · Journal of Computational Chemistry · doi:10.1002/jcc.24764 · Cited by 809 · cited 1×
“In general, there are two important types of VS that are structure-based VS (SBVS) and ligand-based VS (LBVS) [159, 160].”
BackgroundAn Introduction to Machine Learning
Badillo, S., Banfai, B., Birzele, F., Davydov, I. I., Hutchinson, L., Kam‐Thong, T., Siebourg‐Polster, J., Steiert, B., & Zhang, J. D. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1796 · Cited by 799 · cited 1×
“Some describe ML as the primary AI application, while others describe it as a subset of AI [11, 12].”
BackgroundLow Data Drug Discovery with One-Shot Learning
Altae-Tran, H., Ramsundar, B., Pappu, A. S., & Pande, V. (2017) · ACS Central Science · doi:10.1021/acscentsci.6b00367 · Cited by 799 · cited 1×
“A possible solution to deal with this problem is to develop an algorithm that can handle sparse data; one such has been developed by Stanford University named “one-shot learning,” which predicts properties of a drug on the basis of heterogeneous data [482].”
(2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1000 · Cited by 793
The impact of artificial intelligence in medicine on the future role of the physician
Ahuja, A. S. (2019) · PeerJ · doi:10.7717/peerj.7702 · Cited by 789 · cited 1×
“…in AI have impacted clinical pharmacology in many ways like literature searching and processing, interactions with online predictive ML models, ML methods in framing policy to encourage healthcare in many countries and also to get predictive analysis for drug-related information [449, 450].”
MethodMachine-learning approaches in drug discovery: methods and applications
Lavecchia, A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.012 · Cited by 784 · cited 1×
“As a subset of AI, ML is a technique for coordinating VS for drug leads, which generally incorporates gathering a filtered set of compounds, containing known actives and inactive compounds to train a model [423, 424].”
MethodFrom machine learning to deep learning: progress in machine intelligence for rational drug discovery
Zhang, L., Tan, J., Han, D., & Zhu, H. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.010 · Cited by 760 · cited 1×
“Thus, the biggest question that arises in front of pharmaceutical companies is managing the cost and speed of the process [5].”
BackgroundBasics and Recent Advances in Peptide and Protein Drug Delivery
Bruno, B. J., Miller, G. D., & Lim, C. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.104 · Cited by 754 · cited 1×
“Peptides are a biologically active small chain of around 2–50 amino acids, which are increasingly being explored for therapeutic purposes as they have the ability to cross the cellular barrier and can reach the desired target site [109].”
BackgroundArrayExpress--a public database of microarray experiments and gene expression profiles
Parkinson, H., Kapushesky, M., Shojatalab, M., Abeygunawardena, N., Coulson, R., Farne, A., Holloway, E., Kolesnykov, N., Lilja, P., Lukk, M., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl995 · Cited by 752
Neurodegenerative disease: models, mechanisms, and a new hope
Gitler, A. D., Dhillon, P., & Shorter, J. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030205 · Cited by 739 · cited 1×
“Further, these disorders can exhibit varying symptoms like cognitive decline, slow movement, tremors, memory loss, depression, speaking problems, muscle stiffness [460, 461].”
BackgroundA Practical Guide to The Cancer Genome Atlas (TCGA)
Wang, Z., Jensen, M. A., & Zenklusen, J. C. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3578-9_6 · Cited by 723 · cited 1×
“…nlm. nih. gov/ geo/) [41], The Cancer Genome Atlas (TCGA) (https:// www. cancer. gov/ about-nci/ organ izati on/ ccg/ resea rch/ struc tural-genom ics/ tcga) [42], Arrayexpress (https:// www. ebi . ac . uk / array expre ss/) [43], are some of the big repositories which contain gene expression data.”
BackgroundApplications of Deep Learning in Biomedicine
Mamoshina, P., Vieira, A., Lane, E., & Zhavoronkov, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00982 · Cited by 701
Virtual Screening Strategies in Drug Discovery: A Critical Review
Lavecchia, A., & Giovanni, C. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990001 · Cited by 686 · cited 1×
“VS is an efficient method to screen out the promising therapeutic compound from a pool of compounds [158].”
MethodLee, I., Keum, J., & Nam, H. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1007129 · Cited by 675
Drug discovery and development: Role of basic biological research
Mohs, R. C., & Greig, N. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.005 · Cited by 673 · cited 1×
“The current drug discovery challenges are related to the toxicity of the drug, its side effects, choosing the right target site, appropriate dosages, and even intellectual property [447].”
BackgroundArtificial intelligence for clinical trial design
Harrer, S., Shah, P., Antony, B., & Hu, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.005 · Cited by 672 · cited 1×
“Furthermore, after the introduction of AI technology, the success rates of clinical trials have improved drastically [453].”
BackgroundAdvancing drug discovery via artificial intelligence
Chan, H. C. S., Shan, H., Dahoun, T., Vogel, H., & Yuan, S. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.06.004 · Cited by 654
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 653 · cited 1×
“…characteristics features of drug compounds such as SMILES2Vec (predicts chemical properties) [339], Chemception (DNN-based prediction of chemical properties) [245], DeepSynergy (prediction of anti-cancer drug synergy with DL) [340], and deepAOT (prediction of compound acute oral toxicity) [341].”
BackgroundControl of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC
Kucukdereli, H., Allen, N. J., Lee, A. T., Feng, A., Ozlu, M. I., Conatser, L. M., Chakraborty, C., Workman, G., Weaver, M., Sage, E. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104977108 · Cited by 642 · cited 1×
“…ug [ 420 ] vcclab. org/ lab/ pclie nt/) [304], E-DRAGON (http:// www. vcclab. org/ lab/ edrag on/) [304], ChemSpider (http:// www. chems pider. com/) [306], SPARC (http:// sparc. chem. uga. edu/ sparc/) [307], and OSIRIS property explorer (https:// www. organ ic-chemi stry. org/ prog/ peo/) [308].”
Amini, A., & Cheng, C. (2013) · Scientific Reports · doi:10.1038/srep03316 · Cited by 594
Viewpoint: when will AI exceed human performance? evidence from AI experts
Grace, K., Salvatier, J., Dafoe, A., Zhang, B., & Evans, O. (2018) · Journal of Artificial Intelligence Research · doi:10.1613/jair.1.11222 · Cited by 579
Exploiting machine learning for end-to-end drug discovery and development
Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019) · Nature Materials · doi:10.1038/s41563-019-0338-z · Cited by 578 · cited 1×
“ML models like SVM, RF, DNNs, and many others have been used for drug discovery for analyzing the pharmaceuticals applications from docking to VS [437].”
MethodLusci, A., Pollastri, G., & Baldi, P. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400187y · Cited by 555 · cited 2×
“Similarly, Lusci et al. 2013 constructed a neural network-based model to predict the molecular properties.”
BackgroundMethodHow artificial intelligence is changing drug discovery
Fleming, N. (2018) · Nature · doi:10.1038/d41586-018-05267-x · Cited by 546
Predicting drug response and synergy using a deep learning model of human cancer cells
Kuenzi, B. M., Park, J., Fong, S. H., Sanchez, K. S., Lee, J., Kreisberg, J. F., Ma, J., & Ideker, T. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.014 · Cited by 544 · cited 1×
“Similarly, Kuenzi et al. 2020 predicted drug response and synergy using a DL model of human cancer cells.”
MethodGradient Theory of Optimal Flight Paths
KELLEY, H. J. (1960) · ARS Journal · doi:10.2514/8.5282 · Cited by 542 · cited 1×
“Henry J. Kelley developed the continuous backpropagation model in 1960, and a simpler version based only on-chain rule was developed by Stuart Dreyfus in 1962 [22, 23].”
BackgroundKarimi, M., Wu, D., Wang, Z., & Shen, Y. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz111 · Cited by 536
deepDR: a network-based deep learning approach to in silico drug repositioning
Zeng, X., Zhu, S., Liu, X., Zhou, Y., Nussinov, R., & Cheng, F. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz418 · Cited by 535 · cited 2×
“The results concluded that deepDR predicted approved drugs such as risperidone and aripiprazole for the treatment of Alzheimer’s disease (AD), whereas methylphenidate and pergolide for treatment of Parkinson’s disease (PD) [291].”
BackgroundMethodPathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00001 · Cited by 531
Troyanskaya, O. G., Dolinski, K., Owen, A. B., Altman, R. B., & Botstein, D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0832373100 · Cited by 527
Yao, Z.-J., Dong, J., Che, Y.-J., Zhu, M.-F., Wen, M., Wang, N.-N., Wang, S., Lu, A.-P., & Cao, D.-S. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9915-2 · Cited by 514
An evaluation of the implementation of the Cramer classification scheme in the Toxtree software
Patlewicz, G., Jeliazkova, N., Safford, R. J., Worth, A. P., & Aleksiev, B. (2008) · SAR and QSAR in Environmental Research · doi:10.1080/10629360802083871 · Cited by 512 · cited 1×
“For this different web-based tools have been developed such as LimTox (http:// limtox. bioin fo. cnio. es/) [321], pkCSM (http:// biosig. unime lb. edu. au/ pkcsm/) [322], admetSAR (http:// lmmd. ecust. edu. cn/ admet sar2/) [323], and Toxtree (http:// toxtr ee. sourc eforge. net/) [324].”
MethodGoogle DeepMind and healthcare in an age of algorithms
Powles, J., & Hodson, H. (2017) · Health and Technology · doi:10.1007/s12553-017-0179-1 · Cited by 511 · cited 1×
“Recently, Google’s DeepMind (https:// github. com/ deepm ind) has devised an AI-based tool trained on PDB structural data, referred to as AlphaFold, which can predict the 3D structure of proteins from their amino acid sequences [74].”
MethodPolypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498 · cited 1×
“It is best suited for designing a promising therapeutic agent for more complex diseases such as cancer, neurodegenerative disease (NDDs), diabetes, heart failure, and many others [353–355].”
BackgroundQSAR-Based Virtual Screening: Advances and Applications in Drug Discovery
Neves, B. J., Braga, R. C., Melo-Filho, C. C., Moreira-Filho, J. T., Muratov, E. N., & Andrade, C. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01275 · Cited by 494
DeepPurpose: a deep learning library for drug–target interaction prediction
Huang, K., Fu, T., Glass, L. M., Zitnik, M., Xiao, C., & Sun, J. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa1005 · Cited by 484
Zhang, D.-H., Wu, K.-L., Zhang, X., Deng, S.-Q., & Peng, B. (2020) · Journal of Integrative Medicine · doi:10.1016/j.joim.2020.02.005 · Cited by 482 · cited 1×
“The results concluded that 13 existing Chinese traditional medicines were effective against novel coronavirus [69].”
ResultSchütt, K. T., Gastegger, M., Tkatchenko, A., Müller, K.-R., & Maurer, R. J. (2019) · Nature Communications · doi:10.1038/s41467-019-12875-2 · Cited by 476 · cited 1×
“With these data, we can determine the electronic properties of molecules, the arrangement of chemical bonds around a molecule, and the location of reactive sites [78].”
BackgroundSMPDB 2.0: Big Improvements to the Small Molecule Pathway Database
Jewison, T., Su, Y., Disfany, F. M., Liang, Y., Knox, C., Maciejewski, A., Poelzer, J., Huynh, J., Zhou, Y., Arndt, D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1067 · Cited by 474
Open Targets Platform: new developments and updates two years on
Carvalho-Silva, D., Pierleoni, A., Pignatelli, M., Ong, C., Fumis, L., Karamanis, N., Carmona, M., Faulconbridge, A., Hercules, A., McAuley, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1133 · Cited by 472 · cited 1×
““OpenTargets” (https:// www. opent argets. org/) [374], a freeware and ML-based tool, used for prioritizing potential therapeutic drug targets with over 71% accuracy.”
MethodAn Introduction to Machine Learning
Kubat, M. (2017) · doi:10.1007/978-3-319-63913-0 · Cited by 445 · cited 1×
“DL is a subset of ML, which itself is a subset of AI, and thus, the evolution goes like AI > ML > DL [13, 14].”
BackgroundVatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429 · cited 1×
“Moreover, the number of startups in this field has also escalated and reached 230 by June 2020 [476].”
BackgroundAn, J., Yang, J., Wang, Y., Wang, Y., Xu, B., Xie, G., Chai, S., Liu, X., Xu, S., Wen, X., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00001 · Cited by 424
Keenan, A. B., Jenkins, S. L., Jagodnik, K. M., Koplev, S., He, E., Torre, D., Wang, Z., Dohlman, A. B., Silverstein, M. C., Lachmann, A., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2017.11.001 · Cited by 423 · cited 1×
“Additionally, the library of integrated network-based cellular signature (LINCS) L1000 (https:// lincs proje ct. org/ LINCS/) [60] is another repository that contains information on the change in gene expression signatures of human cell lines when treated with different chemical compounds.”
BackgroundApplication of Generative Autoencoder in De Novo Molecular Design
Blaschke, T., Olivecrona, M., Engkvist, O., Bajorath, J., & Chen, H. (2018) · Molecular Informatics · doi:10.1002/minf.201700123 · Cited by 411
Vaga, S., Lee, S., Ji, B., Andreasson, A., Talley, N. J., Agréus, L., Bidkhori, G., Kovatcheva-Datchary, P., Park, J., Lee, D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71939-2 · Cited by 410
ChemDes: an integrated web-based platform for molecular descriptor and fingerprint computation
Dong, J., Cao, D.-S., Miao, H.-Y., Liu, S., Deng, B.-C., Yun, Y.-H., Wang, N.-N., Lu, A.-P., Zeng, W.-B., & Chen, A. F. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0109-z · Cited by 404
SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening
Zoete, V., Daina, A., Bovigny, C., & Michielin, O. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00174 · Cited by 404
AiZynthFinder: a fast, robust and flexible open-source software for retrosynthetic planning
Genheden, S., Thakkar, A., Chadimová, V., Reymond, J.-L., Engkvist, O., & Bjerrum, E. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00472-1 · Cited by 378
Artificial Intelligence in Drug Design
Hessler, G., & Baringhaus, K.-H. (2018) · Molecules · doi:10.3390/molecules23102520 · Cited by 373 · cited 2×
“The primary application for this strategy was adequate, with 4 out of 5 atoms indicating the ideal action [435].”
BackgroundDe Novo Design of Bioactive Small Molecules by Artificial Intelligence
Merk, D., Friedrich, L., Grisoni, F., & Schneider, G. (2018) · Molecular Informatics · doi:10.1002/minf.201700153 · Cited by 373
End-to-End Differentiable Learning of Protein Structure
AlQuraishi, M. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.006 · Cited by 371
Predicting Protein–Protein Interactions from the Molecular to the Proteome Level
Keskin, O., Tuncbag, N., & Gursoy, A. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00683 · Cited by 369 · cited 1×
“If two proteins’ genes are not close by in the genome, then this method cannot reliably predict an interaction between these two genes [156, 157].”
Performance of machine-learning scoring functions in structure-based virtual screening.
Wójcikowski, M., Ballester, P. J., & Siedlecki, P. (2017) · Scientific Reports · doi:10.1038/srep46710 · Cited by 364 · cited 1×
“Further, ML models such as PARASHIFT, HEX, USR, and ShaPE algorithms have been constructed for LBVS [168, 169].”
MethodOpen-source platform to benchmark fingerprints for ligand-based virtual screening
Riniker, S., & Landrum, G. A. (2013) · Journal of Cheminformatics · doi:10.1186/1758-2946-5-26 · Cited by 359 · cited 1×
“…and tools have been developed for LBVS such as SwissSimilarity (http:// www. swiss simil arity. ch/) [198], METADOCK [199], Open-source platform [200], HybridSim-VS (http:// www. rcidm. org/ Hybri dSim-VS/) [201], PKRank [202], PyGOLD (http:// www. agkoch. de/) [203], BRUSELAS (http:// bio-hpc.…”
MethodHomology modeling in drug discovery: Overview, current applications, and future perspectives
Muhammed, M. T., & Aki‐Yalcin, E. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13388 · Cited by 358 · cited 1×
“Thus, a technique like homology modeling has been developed to overcome this hindrance [297].”
MethodL1000CDS2: LINCS L1000 characteristic direction signatures search engine
Duan, Q., Reid, S. P., Clark, N. R., Wang, Z., Fernandez, N. F., Rouillard, A. D., Readhead, B., Tritsch, S. R., Hodos, R., Hafner, M., et al. (2016) · npj Systems Biology and Applications · doi:10.1038/npjsba.2016.15 · Cited by 355 · cited 1×
“LINCS L1000 data-driven search engine, known as L1000CDS 2 , is an open-access search engine that contains data of drugs that can revert the expression of differentially expressed genes; hence, they too can be used for drug discovery [61].”
BackgroundJing, Y., Bian, Y., Hu, Z., Wang, L., & Xie, X.-Q. S. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0210-0 · Cited by 351 · cited 1×
“Moreover, with the advent of ML-based tools, it has become relatively easier to determine the three-dimensional structure of a target protein, which is a critical step in drug discovery, as novel drugs are designed based on the three-dimensional ligand biding environment of a protein [72, 73].”
BackgroundKadurin, A., Aliper, A., Kazennov, A., Mamoshina, P., Vanhaelen, Q., Khrabrov, K., & Zhavoronkov, A. (2017) · Oncotarget · doi:10.18632/oncotarget.14073 · Cited by 350
Luechtefeld, T., Marsh, D., Rowlands, C., & Hartung, T. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy152 · Cited by 327 · cited 1×
“Recently, other ML-based tools such as SPIDER [342] and read-across structure–activity relationships (RASAR) [343] were developed, which are capable of analyzing β-lapachone targets and linking molecular structures and toxic properties of an unknown compound, respectively.”
MethodThe NCI Genomic Data Commons as an engine for precision medicine
Jensen, M. A., Ferretti, V., Grossman, R. L., & Staudt, L. M. (2017) · Blood · doi:10.1182/blood-2017-03-735654 · Cited by 324 · cited 1×
“The National Cancer Institute Genomic Data Commons (NCIGDC) (https:// gdc. cancer. gov/) [50] and TCGA are data repositories that contain sequencing data related to cancer.”
BackgroundIn Silico Models for Designing and Discovering Novel Anticancer Peptides
Tyagi, A., Kapoor, P., Kumar, R., Chaudhary, K., Gautam, A., & Raghava, G. P. S. (2013) · Scientific Reports · doi:10.1038/srep02984 · Cited by 320 · cited 1×
“Likewise, Tyagi et al. 2013 developed an SVM-based platform for identifying new anti-cancer peptides [115].”
A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials
Gayvert, K. M., Madhukar, N. S., & Elemento, O. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.07.023 · Cited by 310 · cited 1×
“DeepTox (http:// bioinf. jku. at/ resea rch/ DeepT ox/ tox21. html) [334] and PrOCTOR (https:// github. com/ kgayv ert/ PrOCT OR) [335], are used for prediction of toxicity of new compounds and prediction of the toxicity probability in clinical trials, respectively.”
MethodThe significance of artificial intelligence in drug delivery system design
Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.001 · Cited by 305 · cited 1×
“However, these techniques also impose challenges such as inaccuracy and inefficiency [3].”
BackgroundYou, Z.-H., Lei, Y.-K., Zhu, L., Xia, J., & Wang, B. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-s8-s10 · Cited by 304 · cited 1×
“A novel hierarchical model PCA-ensemble extreme learning machine (PCA-EELM) to predict protein–protein interactions only using protein sequences information has appeared as a powerful tool that gives output with accuracy and less duration [150].”
MethodWang, J., Luo, C., Shan, C., You, Q., Lu, J., Elf, S., Zhou, Y., Wen, Y., Vinkenborg, J. L., Fan, J., et al. (2015) · Nature Chemistry · doi:10.1038/nchem.2381 · Cited by 301 · cited 1×
“Similarly, identification of human copper trafficking blocker in cancer [369], identification of multi-target ligands through chemical-protein interaction in AD [370], prediction of the anticancer mechanism of Kushen Injection against Hepato-cellular carcinoma [371], and discovery of…”
BackgroundMTiOpenScreen: a web server for structure-based virtual screening
Labbé, C. M., Rey, J., Lagorce, D., Vavruša, M., Becot, J., Sperandio, O., Villoutreix, B. O., Tufféry, P., & Miteva, M. A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv306 · Cited by 292 · cited 1×
“For example, tools such as MTiOpenScreen (http:// biose rv. rpbs. univ- paris-dider ot. fr/ servi ces/ MTiOp enScr een/) [170], FlexX ‐ Scan [171], CompScore (http:// bioqu imio. udla. edu. ec/ comps core/) [172], PlayMolecule BindScope (PlayMol-ecule.org) [173], GeauxDock (http:// www. bryli nski.…”
MethodDeep-AmPEP30: Improve Short Antimicrobial Peptides Prediction with Deep Learning
Yan, J., Bhadra, P., Li, A., Sethiya, P., Qin, L., Tai, H. K., Wong, K. H., & Siu, S. W. I. (2020) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2020.05.006 · Cited by 291
Wang, X., Pan, C., Gong, J., Liu, X., & Li, H. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00690 · Cited by 290
Liu, M., Wu, Y., Chen, Y., Sun, J., Zhao, Z., Chen, X.-W., Matheny, M. E., & Xu, H. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000699 · Cited by 289 · cited 1×
“In addition, Liu et al. [141] integrated chemical, biological, phenotypic properties of drugs to predict ADR associated with it via machine learning analysis.”
BackgroundIn silico clinical trials: how computer simulation will transform the biomedical industry
Viceconti, M., Henney, A., & Morley-Fletcher, E. (2016) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20161408 · Cited by 289
Bai, Q., Tan, S., Xu, T., Liu, H., Huang, J., & Yao, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa161 · Cited by 287 · cited 1×
“For example, Q.Bai et al. 2020 have devised MolAIcal (https:// molai cal. github. io/), a tool that can design three-dimensional drugs in three-dimensional protein pockets [82].”
BackgroundDeepPPI: Boosting Prediction of Protein–Protein Interactions with Deep Neural Networks
Du, X., Sun, S., Hu, C., Yao, Y., Yan, Y., & Zhang, Y. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00028 · Cited by 286 · cited 1×
“Further, DNNs PPIs prediction efficiency was improved by a novel method known as DNN for protein–protein interactions prediction (DeepPPI) (http:// ailab. ahu. edu. cn: 8087/ DeepP PI/ index. html) [151].”
MethodWhen Will AI Exceed Human Performance? Evidence from AI Experts
Grace, K., Salvatier, J., Dafoe, A., Zhang, B., & Evans, O. (2017) · arXiv · doi:10.48550/arxiv.1705.08807 · Cited by 285
Bioactive Molecule Prediction Using Extreme Gradient Boosting
Babajide Mustapha, I., & Saeed, F. (2016) · Molecules · doi:10.3390/molecules21080983 · Cited by 278
Can cell systems biology rescue drug discovery?
Butcher, E. C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1754 · Cited by 276
Automatic prediction of protein function
Wrzeszczynski, K. O., Ofran, Y., Rost, B., Nair, R., & Liu, J. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3114-8 · Cited by 271
Recurrent Neural Network Model for Constructive Peptide Design
Müller, A. T., Hiss, J. A., & Schneider, G. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00414 · Cited by 270 · cited 1×
“It was observed that RNNs have the potential to utilize SMILES strings for drug designing [429].”
MethodComputational drug repositioning using low-rank matrix approximation and randomized algorithms
Luo, H., Li, M., Wang, S., Liu, Q., Li, Y., & Wang, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty013 · Cited by 264 · cited 1×
“…DPDR-CPI (http:// cpi. bio-x. cn/ dpdr/) [276], PHARMGKB (https:// www. pharm gkb. org/) [277], PRO-MISCUOUS 2.0 (http:// bioin forma tics. chari te. de/ promi scuou s2) [278], and DRRS (http:// bioin forma tics. csu. edu. cn/ resou rces/ softs/ DrugR eposi tioni ng/ DRRS/ index. html) [279].”
InfluentialApplying machine learning techniques to predict the properties of energetic materials
Elton, D. C., Boukouvalas, Z., Butrico, M. S., Fuge, M. D., & Chung, P. W. (2018) · Scientific Reports · doi:10.1038/s41598-018-27344-x · Cited by 263
Is Multitask Deep Learning Practical for Pharma?
Ramsundar, B., Liu, B., Wu, Z., Verras, A., Tudor, M., Sheridan, R. P., & Pande, V. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00146 · Cited by 263 · cited 1×
“Moreover, in comparison with AI and ML algorithms, DL provides a much more flexible architecture to create a neural network for a specific problem [477–480].”
ResultTransformer-CNN: Swiss knife for QSAR modeling and interpretation
Karpov, P., Godin, G., & Tetko, I. V. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00423-w · Cited by 262
Proceedings of the 28th International Conference on Neural Information Processing Systems - Volume 1
Cortes, C., Lee, D. D., Sugiyama, M., & Garnett, R. (2015) · Cited by 260
Huang, R., Xia, M., Sakamuru, S., Zhao, J., Shahane, S. A., Attene-Ramos, M., Zhao, T., Austin, C. P., & Simeonov, A. (2016) · Nature Communications · doi:10.1038/ncomms10425 · Cited by 259
Artificial intelligence in drug design
Zhong, F., Xing, J., Li, X., Liu, X., Fu, Z., Xiong, Z., Lu, D., Wu, X., Zhao, J., Tan, X., et al. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9342-2 · Cited by 259 · cited 1×
“…modeling based on AI and ML principles provides a great avenue for identification and validation of chemical compounds, target identification, peptide synthesis, evaluation of drug toxicity and physiochemical properties, drug monitoring, drug efficacy and effectiveness, and drug repositioning [9].”
MethodThe Tox21 robotic platform for the assessment of environmental chemicals – from vision to reality
Attene-Ramos, M. S., Miller, N., Huang, R., Michael, S., Itkin, M., Kavlock, R. J., Austin, C. P., Shinn, P., Simeonov, A., Tice, R. R., et al. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.015 · Cited by 255 · cited 1×
“…of different toxicity prediction software and web-based tools such as Tox21 (https:// ntp. niehs. nih. gov/ whatw estudy/ tox21/ index. html) [327], SEA (http:// sea. bkslab. org/) [328], eToxPred (https:// www. bryli nski. org/ etoxp red-0) [329], and TargeTox (https:// github. com/…”
vNN Web Server for ADMET Predictions
Schyman, P., Liu, R., Desai, V., & Wallqvist, A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00889 · Cited by 254 · cited 1×
“…are publicly available like ChEMBL, PubChem, and ZINC, we have access to millions of compounds annotating information like their structure, known targets and purchasability; MMP plus ML can predict bioactivity like oral exposure, intrinsic clearance, ADMET, and method of action [98, 104, 105].”
BackgroundXu, Y., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00244 · Cited by 250 · cited 1×
“…characteristics features of drug compounds such as SMILES2Vec (predicts chemical properties) [339], Chemception (DNN-based prediction of chemical properties) [245], DeepSynergy (prediction of anti-cancer drug synergy with DL) [340], and deepAOT (prediction of compound acute oral toxicity) [341].”
BackgroundSMILES2Vec: An Interpretable General-Purpose Deep Neural Network for Predicting Chemical PropertiesPreprint
Goh, G. B., Hodas, N. O., Siegel, C., & Vishnu, A. (2017) · arXiv (Cornell University) · doi:10.48550/arxiv.1712.02034 · Cited by 249 · cited 1×
“…which predicts the toxicity properties and chemical characteristics features of drug compounds such as SMILES2Vec (predicts chemical properties) [339], Chemception (DNN-based prediction of chemical properties) [245], DeepSynergy (prediction of anti-cancer drug synergy with DL) [340], and…”
BackgroundFeinstein, W. P., & Brylinski, M. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0067-5 · Cited by 244 · cited 1×
“D structural information of protein or target has been elucidated either through in vitro or in vivo experiments or through computational modeling [162, 163].”
BackgroundComprehensive ensemble in QSAR prediction for drug discovery
Kwon, S., Bae, H., Jo, J., & Yoon, S. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3135-4 · Cited by 243
Artificial Intelligence Approaches for Rational Drug Design and Discovery
Duch, W., Swaminathan, K., & Meller, J. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780765954 · Cited by 243 · cited 1×
“Artificial intelligence (AI), including deep learning (DL) and machine learning (ML) algorithms, has emerged as a possible solution, which can overcome problems and hurdles in the drug design and discovery process [4].”
BackgroundRifaioglu, A. S., Nalbat, E., Atalay, V., Martin, M. J., Cetin-Atalay, R., & Doğan, T. (2020) · Chemical Science · doi:10.1039/c9sc03414e · Cited by 240
Lu, L., Lu, H., & Skolnick, J. (2002) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10222 · Cited by 240 · cited 1×
“In this method, proteins with known template structures are rethreaded, and their interaction with other proteins, their interfacial energy, and Z-score are established [154].”
MethodA multiple kernel learning algorithm for drug-target interaction prediction
Nascimento, A. C. A., Prudêncio, R. B. C., & Costa, I. G. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0890-3 · Cited by 235
Repurposing High-Throughput Image Assays Enables Biological Activity Prediction for Drug Discovery
Simm, J., Klambauer, G., Arany, A., Steijaert, M., Wegner, J. K., Gustin, E., Chupakhin, V., Chong, Y. T., Vialard, J., Buijnsters, P., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.01.015 · Cited by 232 · cited 1×
“Similarly, using DeepTox, Simm et al. 2018 analyzed and repurposed high-throughput imaging assay data to predict the biological activity of different chemical compounds that were targeting alternative biological pathways and processes [338].”
MethodChoudhary, S., Malik, Y. S., & Tomar, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01664 · Cited by 231
Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
Hussain, R., Zubair, H., Pursell, S., & Shahab, M. (2018) · Brain Sciences · doi:10.3390/brainsci8090177 · Cited by 229 · cited 1×
“The aggregation of toxic, misfolded, cytoplasmic proteins in different brain regions is one of the primary reasons for the inception of these disorders [459].”
BackgroundReker, D., Rodrigues, T., Schneider, P., & Schneider, G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320001111 · Cited by 227 · cited 1×
“…ed/) [140], Self-Organizing Map Based Prediction of Drug Equivalence Relationship (SPiDER) (http:// modla bcadd. ethz . ch/ softw are/ spider) [357], Targethunter (https:// www. cblig and. org / Targe tHunt er3D/) [358], PharmMapper (http:// lilab-ecust. cn / pharm mapper/) [359], ChemMapper…”
BackgroundIn silico methods to address polypharmacology: current status, applications and future perspectives
Lavecchia, A., & Cerchia, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.12.007 · Cited by 225 · cited 1×
“However, many issues like time cost, computational cost, and reliability, are still associated with traditional computational methods [70, 71].”
BackgroundC5. 0 Algorithm to Improved Decision Tree with Feature Selection and Reduced Error Pruning
Pandya, R., & Pandya, J. (2015) · International Journal of Computer Applications · doi:10.5120/20639-3318 · Cited by 223 · cited 1×
“The constructed models were used to evaluate rat oral acute toxicity, respiratory toxicity, and urinary tract toxicity [345–348].”
MethodDrugNet: Network-based drug–disease prioritization by integrating heterogeneous data
Martínez, V., Navarro, C., Cano, C., Fajardo, W., & Blanco, A. (2015) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2014.11.003 · Cited by 214 · cited 1×
“Thus, different AI-based algorithm and web-based tools have been developed in recent times such as DrugNet (http:// genom e2. ugr. es/ drugn et/) [274], DRIMC (https:// github. com/ linwa ng1982/ DRIMC) [275], DPDR-CPI (http:// cpi. bio-x. cn/ dpdr/) [276], PHARMGKB (https:// www. pharm gkb. org/)…”
MethodYi, H.-C., You, Z.-H., Zhou, X., Cheng, L., Li, X., Jiang, T.-H., & Chen, Z.-H. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.04.025 · Cited by 214 · cited 1×
“Similarly, Yi et al. 2019 devised ACP-DL (https:// github. com/ haich engyi/ ACP-DL), a DL-based tool for the discovery of novel anti-cancer peptides [113].”
MethodWang, L., Ma, C., Wipf, P., Liu, H., Su, W., & Xie, X.-Q. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9449-z · Cited by 214 · cited 1×
“…Relationship (SPiDER) (http:// modla bcadd. ethz . ch/ softw are/ spider) [357], Targethunter (https:// www. cblig and. org / Targe tHunt er3D/) [358], PharmMapper (http:// lilab-ecust. cn / pharm mapper/) [359], ChemMapper (http:// lilab. ecust . edu . cn/ chemm apper/) [360], and Swiss Target…”
Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties
Obrezanova, O., Csányi, G., Gola, J. M. R., & Segall, M. D. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci7000633 · Cited by 213
eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates
Pu, L., Naderi, M., Liu, T., Wu, H.-C., Mukhopadhyay, S., & Brylinski, M. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0282-6 · Cited by 212 · cited 1×
“…prediction software and web-based tools such as Tox21 (https:// ntp. niehs. nih. gov/ whatw estudy/ tox21/ index. html) [327], SEA (http:// sea. bkslab. org/) [328], eToxPred (https:// www. bryli nski. org/ etoxp red-0) [329], and TargeTox (https:// github. com/ artem-lysen ko/ Targe Tox) [330].”
Gong, J., Cai, C., Liu, X., Ku, X., Jiang, H., Gao, D., & Li, H. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt270 · Cited by 211 · cited 1×
“…(https:// www. cblig and. org / Targe tHunt er3D/) [358], PharmMapper (http:// lilab-ecust. cn / pharm mapper/) [359], ChemMapper (http:// lilab. ecust . edu . cn/ chemm apper/) [360], and Swiss Target Prediction (Swis-sTargetPrediction) (http:// www. swiss targe tpred iction. ch /) [361].”
BackgroundChu, Y., Kaushik, A. C., Wang, X., Wang, W., Zhang, Y., Shan, X., Salahub, D. R., Xiong, Y., & Wei, D.-Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz152 · Cited by 208
Machine Learning in Virtual Screening
Melville, J., Burke, E., & Hirst, J. (2009) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620709788167980 · Cited by 203 · cited 1×
“Moreover, AI-based algorithms have been developed for molecular dynamic simulation assays in SBVS [167].”
MethodZang, Q., Mansouri, K., Williams, A. J., Judson, R. S., Allen, D. G., Casey, W. M., & Kleinstreuer, N. C. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00625 · Cited by 198 · cited 1×
“In 2016, Zang et al. developed an ML-based model for the prediction of physicochemical properties such as octanol–water partition coefficient, water solubility, boiling point, melting point, vapor pressure, and bioconcentration factors of environmental chemicals [303].”
BackgroundCarpenter, K. A., & Huang, X. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180607124038 · Cited by 197 · cited 1×
“The trained model is then validated, and if it is accurate enough, the model is used on new data sets to screen compounds with desired activity against a target [165].”
MethodWu, Z., Zhu, M., Kang, Y., Leung, E. L.-H., Lei, T., Shen, C., Jiang, D., Wang, Z., Cao, D., & Hou, T. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa321 · Cited by 197 · cited 1×
“Further, Wu et al. 2020 applied ML models, namely structural profile prediction model and biological profile prediction model, to predict anti-fibrosis drug candidates.”
MethodOptimal medication dosing from suboptimal clinical examples: a deep reinforcement learning approach
Nemati, S., Ghassemi, M. M., & Clifford, G. D. (2016) · 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2016.7591355 · Cited by 195 · cited 1×
“Likewise, Nemati et al. [126] developed a deep reinforcement learning model trained on multipa-rameter intelligent monitoring in intensive care II database (MIMIC II) to find an ideal dose of another anticoagulant drug, heparin.”
BackgroundLevenson, R. W., Sturm, V. E., & Haase, C. M. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153653 · Cited by 190 · cited 1×
“Further, these disorders can exhibit varying symptoms like cognitive decline, slow movement, tremors, memory loss, depression, speaking problems, muscle stiffness [460, 461].”
BackgroundLópez-Isac, E., Acosta-Herrera, M., Kerick, M., Assassi, S., Satpathy, A. T., Granja, J., Mumbach, M. R., Beretta, L., Simeón, C. P., Carreira, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12760-y · Cited by 184 · cited 1×
“Further, GWAS studies conducted by Isac-Lopez et al. [377] predicted the multiple risk loci and highlighted fibrotic and vasculopathy pathways.”
ResultComputational prediction of chemical reactions: current status and outlook
Engkvist, O., Norrby, P.-O., Selmi, N., Lam, Y.-H., Peng, Z., Sherer, E. C., Amberg, W., Erhard, T., & Smyth, L. A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.014 · Cited by 182 · cited 1×
“Five atoms were combined in light of such a methodology, and the plan action could be affirmed for four particles against atomic, chemical receptors [434].”
BackgroundComputational Multitarget Drug Design
Zhang, W., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00491 · Cited by 180
Current Concepts of Neurodegenerative Mechanisms in Alzheimer’s Disease
Magalingam, K. B., Radhakrishnan, A., Ping, N. S., & Haleagrahara, N. (2018) · BioMed Research International · doi:10.1155/2018/3740461 · Cited by 178
Lei, T., Li, Y., Song, Y., Li, D., Sun, H., & Hou, T. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0117-7 · Cited by 174 · cited 1×
“The constructed models were used to evaluate rat oral acute toxicity, respiratory toxicity, and urinary tract toxicity [345–348].”
Methodlazar: a modular predictive toxicology framework
Maunz, A., Gütlein, M., Rautenberg, M., Vorgrimmler, D., Gebele, D., & Helma, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00038 · Cited by 174
The numerical solution of variational problems
Dreyfus, S. (1962) · Journal of Mathematical Analysis and Applications · doi:10.1016/0022-247x(62)90004-5 · Cited by 172 · cited 1×
“Henry J. Kelley developed the continuous backpropagation model in 1960, and a simpler version based only on-chain rule was developed by Stuart Dreyfus in 1962 [22, 23].”
BackgroundAutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization
Spiegel, J. O., & Durrant, J. D. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00429-4 · Cited by 171
Improving chemical similarity ensemble approach in target prediction
Wang, Z., Liang, L., Yin, Z., & Lin, J. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0130-x · Cited by 171 · cited 1×
“…prediction software and web-based tools such as Tox21 (https:// ntp. niehs. nih. gov/ whatw estudy/ tox21/ index. html) [327], SEA (http:// sea. bkslab. org/) [328], eToxPred (https:// www. bryli nski. org/ etoxp red-0) [329], and TargeTox (https:// github. com/ artem-lysen ko/ Targe Tox) [330].”
Research works printed but not linked: 5
- Carpenter KA, Huang X (2018) Machine learning-based virtual screening and its applications to Alzheimer’s drug discovery: a review. Curr Pharm Des. https://doi.org/10.2174/1381612824666180607124038 · DOI · Paper page
- Gad SC (2014) QSAR. In: Third E (ed) Wexler PBT- Encyclopedia of Toxicology. Academic Press, Oxford, pp 1–9
- Royal Society of Chemistry (2015) ChemSpider. Search and Share Chemistry. R. Soc, Chem
- Cao X, Fan R, Zeng W (2020) DeepDrug: a general graph-based deep learning framework for drug relation prediction. biorxiv. https://doi.org/10.1101/2020.11.09.375626 · DOI
- Harrer S, Shah P, Antony B, Hu J (2019) Artificial intelligence for clinical trial design. Trends Pharmacol Sci 40:577–591. https://doi.org/10.1016/j.tips.2019.05.005 · DOI · Paper page
Cited by
The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century
Maleki Varnosfaderani, S., & Forouzanfar, M. (2024) · Bioengineering · doi:10.3390/bioengineering11040337 · Cited by 931
“By analyzing historical data from clinical trials and patient records, AI models can predict the effectiveness of drugs on various demographic groups [44,45].”
MethodThe role of AI in drug discovery: challenges, opportunities, and strategies
Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023) · Pharmaceuticals · doi:10.3390/ph16060891 · Cited by 690
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
“Today, AI-based technologies have been applied to virtually every step in the drug discovery process, including target identification, drug design, drug screening, chemical synthesis, and prediction of the drug’s properties and mode of action.(341,342) In addition, AI can be used to quickly identify lead compounds ext…”
Metaverse for Healthcare: A Survey on Potential Applications, Challenges and Future Directions
Chengoden, R., Victor, N., Huynh-The, T., Yenduri, G., Jhaveri, R. H., Alazab, M., Bhattacharya, S., Hegde, P., Maddikunta, P. K. R., & Gadekallu, T. R. (2023) · IEEE Access · doi:10.1109/access.2023.3241628 · Cited by 508
“Artificial intelligence (AI), also known as machine intelligence, focuses on the development and management of technology that can autonomously learn to make decisions and carry out tasks on behalf of humans [90].”
BackgroundClinical trial design in the era of precision medicine
Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01102-1 · Cited by 305
“Machine-learning and AI technology have the potential to accelerate the process of drug development, reducing failure rates, and increasing the accuracy of predictions [20, 177].”
Background
Metadata
- Authors
- Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P.
- Affiliations
- Delhi Technological University (IN)
- Corresponding author
- Kumar, Pravir
- Venue
- Molecular Diversity
- Published
- 2021-04-12
- Volume
- 25
- Issue
- 3
- Pages
- 1315-1360
- ISSN
- 1381-1991 (ISSN-L)
- 1573-501X
- PMC
- PMC8040371
- OpenAlex
- W3153418506
- Semantic Scholar
- 29409efa04ac99ccf01d2a011d21d5d14e870000
- Cited by
- 1,473
- References
- 503
- Citations by year
- 2026: 221 · 2025: 438 · 2024: 397 · 2023: 272 · 2022: 113 · 2021: 31
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Molecular Diversity (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- artificial intelligence in drug discovery, deep learning, computer-aided drug design, virtual screening, structure-based virtual screening, ligand-based virtual screening, QSAR, pharmacophore modeling, drug repurposing, polypharmacology, toxicity prediction, generative adversarial networks, molecular docking, protein misfolding, biomarker development, drug release monitoring
- MeSH terms
- Machine Learning, Drug Development, Deep Learning, Big Data, Algorithms, Animals, Artificial Intelligence, Humans, Models, Molecular, Research Design, Drug Design, Quantitative Structure-Activity Relationship, Drug Discovery, Data Mining, Chemistry Techniques, Synthetic, Support Vector Machine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.